Furthermore, in esophageal squamous cell carcinoma and lung adenocarcinoma, PSAT1 silencing not only inhibits tumor growth but also acts synergistically with serine deprivation or erlotinib treatment, respectively, to overcome drug resistance in vitro and in vivo (109, 110). Here, PSAT1 is linked to neoplasm.